Significant advances have elevated breast cancer care to new levels of success and complexity. One such advance has been the availability of cyclin-dependent kinase 4 and 6 (CDK 4/6) inhibitors in women with estrogen receptor-positive (ER+) metastatic breast cancer (MBC).
This webcast consists of the faculty presentations from a satellite symposium held June 4, 2016 at the annual oncology meeting that explored the current and expanding pool of information about these agents, as well as best practices for their current and potential use in MBC.
In this presentation, Dr. Harold J. Burstein discusses the mechanistic activity and development history of cyclin-dependent kinase 4/6 inhibitors.
Earn CME credit for a related activity at the following location:
© 2016 Imedex, LLC.